Jiangsu NuoTai AoSaiNuo Biopharmaceutical Co., Ltd.

Nuotai Ausun is a leading Chinese biopharmaceutical company specializing in the research, development, and manufacturing of peptide and small molecule drugs. The company operates a dual business model, providing high-end CDMO services to global pharmaceutical firms while developing its own portfolio of APIs and finished dosages. Nuotai Ausun is particularly recognized for its expertise in large-scale peptide synthesis, supporting blockbuster metabolic treatments like semaglutide and liraglutide. With advanced manufacturing facilities and a robust R&D pipeline, the company serves markets in China, the United States, and Europe. It is listed on the Shanghai Stock Exchange STAR Market.